Patient_Reported_Outcome_Measures_in_Rheumatic_Diseases

239

Measurement instrument

Reliability

Validity

Scale development

Responsiveness

Internal consistency (Cronbach’s a)

Test- retest (ICC) Content

Construct (Pearson or Spearman’s

r )

Concurrent (Pearson or Spearman’s r )

Hypothesis a priori

Confi

rmatory

factor analysis

Rasch analysis

MCID, SDC, ES, Guyatt’s RR or >20 % change in scores

SF-36

0.75–0.97

0.40–0.90

Ceiling

PCS: tophi ( r

= 0.277),

swollen joints ( r

= −0.334),

painful joints ( r

= −0.544),

fl ares last year ( r

= −0.369);

MCS: painful joints ( r

= −0.436),

freq. of fl

ares

( r

= −0.321)

NR

NR

NR

NR

Colchicine: ES for PCS = 0.3 (small), ES for MCS = 0.16 (negligible)

RP = 18.4 %, SF = 32.7 %, RE = 58.6 %

Colchicine + ULT: ES for PCS = 0.99 (large) ES for MCS = 0.08 (negligible), MCID (all subjects) 70 % for PCS and 38 % in MCS

PF 10

0.94

NR

NR

Excellent/very good health = 71.91, good = 74.27, fair/poor = 39.33

HAQ-DI ( r

= −0.75),

SF-36 [0.30 (MH)-0.68 (RP)]

Yes

NR

NR

NR

Modifi

ed with permission from Chandratre P, Roddy E, Clarson L, Richardson J, Hider SL, Mallen CD. Health-related quality of life in

gout: A systematic

review. Rheumatology. 2013 Nov;52(11):2031–2040. By permission of Oxford University Press [

58

]

HAQ-DI

Health Assessment Questionnaire-Disability Index;

GAQ

Gout Assessment Questionnaire,

SF-36

Short Form-36,

PF-10

Physical Functioning

Subscale,

MCS

Mental Component Score,

PCS

Physical Component Score,

MCID

Minimal Clinically Important Difference,

NR

Not reported,

ES

Effect size

9 PROMs for Gouty Arthritis